EMBC
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
Embecta Corp. (EMBC) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | B (3.4) | D+ (1.6) | B (3.4) | B+ (3.6) | C+ (2.6) | B- (2.9) |
| 2026-11-04 | B (3.4) | D+ (1.5) | B (3.4) | B+ (3.5) | C+ (2.7) | B- (2.9) |
| 2026-10-28 | B (3.4) | D+ (1.5) | B (3.4) | C (2.4) | C+ (2.7) | C+ (2.7) |
| 2026-10-21 | B (3.4) | D+ (1.5) | B (3.4) | C (2.3) | C+ (2.6) | C+ (2.6) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe